Financial Gravity Companies Inc. bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 862 shares of the company’s stock, valued at approximately $66,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Contravisory Investment Management Inc. lifted its holdings in Merck & Co., Inc. by 186.4% during the fourth quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock valued at $50,000 after purchasing an additional 425 shares in the last quarter. Arlington Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 93.5% in the fourth quarter. Arlington Partners LLC now owns 828 shares of the company’s stock worth $63,000 after buying an additional 400 shares in the last quarter. Advisors Preferred LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $66,000. Quantamental Technologies LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $109,000. Finally, Legacy Bridge LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $110,000. Institutional investors own 73.46% of the company’s stock.
MRK has been the topic of several research analyst reports. Zacks Investment Research raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a report on Monday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Friday, March 29th. Argus upped their price target on shares of Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 20th. ValuEngine downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research note on Tuesday, February 19th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus price target of $78.74.
NYSE:MRK traded down $0.73 during mid-day trading on Friday, reaching $73.19. The company’s stock had a trading volume of 31,267,836 shares, compared to its average volume of 11,405,758. Merck & Co., Inc. has a 1 year low of $56.26 and a 1 year high of $83.85. The firm has a market cap of $197.33 billion, a PE ratio of 16.86, a price-to-earnings-growth ratio of 1.78 and a beta of 0.63. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.17 and a quick ratio of 0.92.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The company had revenue of $11 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the firm earned $0.98 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 4.65 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 5th. Investors of record on Friday, March 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend was Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Article: How prevalent are 12b-1 fees?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.